| P50 | author | Verena Stiegelbauer | Q114453211 |
| | Matthew Goblirsch | Q114453225 |
| | Annika Wulf-Goldenberg | Q114453238 |
| | Johannes Haybaeck | Q56955634 |
| | George A. Calin | Q64785850 |
| | Xinna Zhang | Q84512732 |
| | Yoshinaga Okugawa | Q88675615 |
| | Armin Gerger | Q88873250 |
| | Martin Pichler | Q90812775 |
| | Petra Vychytilova-Faltejskova | Q103785988 |
| | Gerald Hoefler | Q41609985 |
| | Ajay Goel | Q50723416 |
| | Cristina Ivan | Q56435654 |
| P2093 | author name string | Hui Ling | |
| | Ondrej Slaby | |
| | Marek Svoboda | |
| | Masahisa Ohtsuka | |
| | Elke Winter | |
| P2860 | cites work | Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 |
| | Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer | Q83182157 |
| | A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients | Q87177758 |
| | MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients | Q26865275 |
| | MicroRNA signatures in human cancers | Q27860962 |
| | Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice | Q28118790 |
| | MicroRNA profiles discriminate among colon cancer metastasis | Q33748980 |
| | What do we mean by validating a prognostic model? | Q33849998 |
| | Controversies in the pathological assessment of colorectal cancer | Q34008807 |
| | A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. | Q34240949 |
| | Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells | Q34246676 |
| | MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer | Q34282551 |
| | MicroRNA-188 suppresses G1/S transition by targeting multiple cyclin/CDK complexes | Q34354797 |
| | Colorectal cancer statistics, 2014. | Q34660408 |
| | Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34664272 |
| | MicroRNA classifier and nomogram for metastasis prediction in colon cancer. | Q35332480 |
| | miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression | Q35742473 |
| | The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis | Q36090214 |
| | MicroRNAs in body fluids--the mix of hormones and biomarkers | Q36176435 |
| | MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. | Q36629393 |
| | The future of the TNM staging system in colorectal cancer: time for a debate? | Q36871517 |
| | CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer | Q37138668 |
| | MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis | Q37209436 |
| | MicroRNA signatures: novel biomarker for colorectal cancer? | Q37873226 |
| | Perspectives on current tumor-node-metastasis (TNM) staging of cancers of the colon and rectum | Q37910386 |
| | Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution | Q38257912 |
| | Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes | Q38280129 |
| | Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work | Q38283216 |
| | Loss of polarity protein AF6 promotes pancreatic cancer metastasis by inducing Snail expression | Q38870713 |
| | Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. | Q39561464 |
| | Reporting recommendations for tumor marker prognostic studies (REMARK). | Q53268902 |
| | miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. | Q54340921 |
| | Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. | Q54356802 |
| | Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. | Q54590406 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | carcinogenesis | Q1637543 |
| P304 | page(s) | 1323-1333 | |
| P577 | publication date | 2016-09-06 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis | |
| P478 | volume | 23 | |